Thus, early genetic ibrutinib resistance mutations of PLCG2 may affect the biological impact of subsequent mutations, extending the concept of “genetic canalization” [27] from tumorigenesis to development of resistance to targeted tumor drugs. The gene discussed is PLCG2; the disease is neoplasm.